RxDoctor Payments DataLook up a doctor →

Hong Do

Nurse Practitioner · Burleson, TXNPI 1639683576

Payments from drug & device makers

$17,820in general payments, 2019–2025

Across 797 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Amgen$2K
  • Sanofi$2K
  • Johnson & Johnson$1K
  • Lilly USA, LLC$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • plus $8K from 26 others

What the payments were for

  • Speaking & faculty fees$991%
  • Food & beverage$17,04096%
  • Education$6804%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,820 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$51,830
Medicare patients
149
Services billed
3,292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Unoready PenSecukinumab18$205,531
Humira(Cf) PenAdalimumab11$147,591
OtezlaApremilast20$107,522
SotyktuDeucravacitinib12$82,443
Dupixent PenDupilumab15$57,028
Dupixent SyringeDupilumab14$52,869
JubliaEfinaconazole11$12,219
Clobetasol Propionate219$8,226
Ketoconazole207$3,412
Calcipotriene18$2,352
Tretinoin26$2,305
Tacrolimus19$2,229
Triamcinolone Acetonide169$1,962
Metronidazole28$1,906
Ciclopirox33$1,666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$2,409$107,52220 claims
E.r. Squibb & Sons, L.L.C.Sotyktu$538$82,44312 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$632$12,21911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Burleson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →